Data on SAR-bisPSMA to be presented at EANM
Open PDF
| Stock | Clarity Pharmaceuticals Ltd (CU6.ASX) |
|---|---|
| Release Time | 29 Jun 2026, 9:56 a.m. |
| Price Sensitive | Yes |
This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA.
The summaries are generated by large language models so please interpret with care.
Clarity Pharmaceuticals to Present SAR-bisPSMA Data at EANM
Key Points
- Clarity Pharmaceuticals to present SAR-bisPSMA data at EANM Annual Congress
- 64Cu-SAR-bisPSMA shows improved diagnostic performance over current SOC
- Case reports highlight 67Cu-SAR-bisPSMA's therapeutic potential in mCRPC
- Positive feedback from patients and clinicians on SAR-bisPSMA's impact
Full Summary
Clarity Pharmaceuticals (ASX: CU6) announced the acceptance of data on 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for presentation at the EANM Annual Congress 2026. The data includes a top-rated oral presentation from the Co-PSMA trial, showing 64Cu-SAR-bisPSMA's superior diagnostic performance over current SOC. Case reports also highlight 64Cu-SAR-bisPSMA's ability to detect prostate cancer recurrence where SOC failed. Additionally, data from the SECuRE trial demonstrates 67Cu-SAR-bisPSMA's therapeutic potential in mCRPC, with participants achieving undetectable disease. Both products have shown promising results with mostly mild adverse events.
Sign in to get more information about the company, including guidance changes and other insights.
Sign In